The FDA is concerned that Eli Lilly’s newly approved obesity pill Foundayo might come with a risk for major cardiovascular events and liver damage, and has asked the company to provide data …
Replimune looks ahead as repeat CRL speeds the company’s decline
Replimune’s second complete response letter for its cancer therapy last week is already leading to multiple rounds of layoffs and existential questions about the company’s future unless it can figure out a path forward with …
Error Detection in Emergency Radiology Reports Using a Large Language Model: Multistage Evaluation Study
Background: Emergency radiology requires highly accurate reporting under time constraints; yet, increasing workloads raise the risk of errors. While large language models (LLMs) show potential for proofreading in general radiology, their performance in emergency settings and non-English contexts remains unclear. Objective: We aim to evaluate the performance of a domain-optimized LLM, DeepSeek-R1, for identifying errors […]
Wargame Exercise Demonstrates How Social Media Manipulation Works
In an educational game called “Capture the Narrative,” students created bots to sway a fictional election, simulating influence in real-world political scenarios.
Revolution Medicines leads latest wave of stock offerings, totaling $1.5B
Another stock offering blitz is adding more fuel to biotech investors’ belief in the sector. Revolution Medicines anchored Monday’s offering surge, while Spyre Therapeutics and Allogene Therapeutics also joined in. The trio is planning to …
Endpoints biopharma sentiment survey for Q2 2026
This year is pivotal for biopharma, and we need your perspective on where things are going. Endpoints is fielding the next Biopharma Sentiment Index (BPSI) — a concise, three-minute survey that distills thousands of industry views into a clear quarterly benchmark. The BPSI is one of the most direct snapshots of how people inside biopharma […]
Harbinger raises $100M; Astellas to close Seattle site
Plus, news about Novo Nordisk and OpenAI, and Adcendo’s Series C: 🧪 Flagship’s Harbinger Health raises $100 million for cancer test: The startup said it closed the Series B extension last …
J&J increasingly confident it can manage Stelara cliff, but work remains
Johnson & Johnson executives believe the worst of the biosimilar pressure facing Stelara is behind them, and feel confident enough to predict significant growth through the end of the 2020s. But Wall Street may need …
Eli Lilly to pay up to $300M for cancer biotech CrossBridge Bio
Biotech entrepreneur Michael Torres is selling his antibody-drug conjugate startup CrossBridge Bio to Eli Lilly in a deal worth up to $300 million, the two companies announced Tuesday. Torres, a PhD biologist who previously co-founded …
FDA renews criticism of trial sponsors over transparency
The FDA has launched a drive to get clinical trial sponsors to disclose the results of studies – even if they are negative.
Parker Institute doubles down on cancer vaccines as part of ongoing reboot
At a moment when many drug developers are shying away from politically charged mRNA vaccines, one prominent research funder is doubling down on the technology’s promise to treat and prevent cancer. The Parker Institute for …
Coming soon: 10 Things That Matter in AI Right Now
Each year we compile our 10 Breakthrough Technologies list, featuring our educated predictions for which technologies will have the biggest impact on how we live and work. This year, however, we had a dilemma. While our final picks encompass all our core coverage areas (energy, AI, and biotech, plus a few more), our 2026 list […]